Recent Updates
Recently added Catalysts
AGEN Negative Sentiment Score: 20/100

AGENUS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Agenus Inc. and Encourages Investors to Contact the Firm

Key Takeaway: Agenus Inc. is facing a class action lawsuit filed by Bragar Eagel & Squire, P.C. in the U.S. District Court for Massachusetts. The lawsuit pertains to claims that the company made false and misleading statements about its combination therapy of botensilimab and balstilimab during the class period from January 23, 2023, to July 17, 2024. Investors are encouraged to apply as lead plaintiff by November 5, 2024, as the complaint outlines significant concerns over the clinical efficacy and future prospects of the therapies.

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed against Agenus Inc., indicating legal troubles.
  • The lawsuit alleges materially false and misleading statements regarding Agenus' business and prospects.
  • Claims suggest that the effectiveness of botensilimab and balstilimab was overstated, which may impact investor trust.

Full Press Release Details

NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Agenus Inc. (“Agenus” or the “Company”) (NASDAQ: AGEN) in the United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired Agenus securities between January 23, 2023 and July 17, 2024, both dates inclusive (the “Class Period”). Investors have until November 5, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) the combination therapy of botensilimab and balstilimab was less effective than Defendants had led investors to believe; (2) accordingly, botensilimab and balstilimab's clinical results, as well as their regulatory and commercial prospects, were overstated; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.
If you purchased or otherwise acquired Agenus shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Frequently Asked Questions

What is the class action lawsuit against Agenus Inc. about?

The lawsuit alleges false statements made by Agenus regarding its drug therapies.

Who can participate in the Agenus class action lawsuit?

All individuals or entities that acquired Agenus securities between Jan 23, 2023, and July 17, 2024.

What is the deadline to apply as lead plaintiff?

Investors have until November 5, 2024, to apply to be appointed as lead plaintiff.

How can I contact Bragar Eagel & Squire for more information?

Contact them via email at investigations@bespc.com or call (212) 355-4648.

Is there a cost to join the Agenus lawsuit?

There is no cost or obligation to join the class action lawsuit.

Last updated: Sep 12, 2024